Abstract:Introduction: Diffusion weighted magnetic resonance spectroscopy (DW-MRS) is useful for evaluation of the intracellular environment [1]. Previous studies showed that the most abundant metabolites that are detected by H-MRS are primarily located in the intracellular compartment of the brain and therefore DW-MRS offers excellent tools to specifically measure the intracellular response to cerebral injury [2]. The pathological changes in cells of glioma and metastatic tumor, the most common types of tumor in human brain, are related to the diagnosis and treatment of cerebral tumors. In this study, the apparent diffusion coefficients of brain metabolites were measured by DW-MRS on a clinical MR scanner for detecting pathological changes in cases of glioma and metastatic tumor in human brain. Methods: Ten glioma patients (6 males and 4 females, mean age 46±15.9 years, range 11-62 years) and six metastatic tumor patients (2 males and 4 females, mean age 70±7.6 years, range 65-84 years) were recruited for this study. Twelve age and sexual-matched health controls (4 males and 8 females, mean age 67±8.4 years, range 60-78 years) were selected for metastatic tumor patients. All the controls were free from neurological or psychiatric disease and their brain MRI scans were normal. All subjects had given their permission to be part of the study which was proved by the Investigational Review Board at our hospital. The DW-MRS sequence based on point resolved spectroscopy (PRESS) sequence technique was implemented for this study. The equipment used for the MR examinations was a 3.0T clinical wholebody system (Signa EXCITE HD; General Electric, Milwaukee, WI) with gradients with a maximum amplitude 40 mT/m and a maximum slew rate 150 mT/m/ms. Parameters for the DW-MRS sequence were as follows: TR 2000 ms, TE 144 ms, voxel size 2×2×2 cm (8 mL), spectral width 5000 HZ, and data points 4096. Data were acquired at only two different b-factor values: 45 and 1050 s/mm. The region of interests of DW-MRS were located in 1) the lesion area of glioma patients and its opposite un-affected areas; 2) the lesion area of metastatic tumor patients and 3) the left frontal cortex of health controls (Fig. 1). Post-spectral processing was carried out by SAGE software (GE Medical Systems). Pure water subtraction was used to reduce residual water from each suppressed frame. Phase corrections were performed before the summation of FIDs. Since the integral peak area was more sensitive to the random noise [4], peak height was used to determine the signal intensity of metabolites in this study. The apparent diffusion coefficients (ADCs) value was estimated by the following equation: ( ) ( ) ( ) 2 1 2 1 ADC=-ln S b S b b -b ⎡ ⎤ ⎣ ⎦ Where S (b1), and S (b2) are the signal intensities for the two b-values, b1 and b2.

Absolute Metabolite Quantification in Individuals with Glioma and Healthy Individuals Using Whole-Brain Three-dimensional MR Spectroscopic and Echo-planar Time-resolved Imaging

Absolute quantification of cerebral metabolites using 2D 1H-MRSI with quantitative MRI-based water reference

Metabolic Approach for Tumor Delineation in Glioma Surgery: 3d Mr Spectroscopy Image-Guided Resection

Quantitative diffusion weighted magnetic resonance spectroscopy of glioma and metastatic tumor in human brain in vivo

Noninvasive Delineation of Glioma Infiltration with Combined 7T Chemical Exchange Saturation Transfer Imaging and MR Spectroscopy: A Diagnostic Accuracy Study

Combined 7T CEST/MRS Imaging to Predict Tumor Metabolism in Glioma

Convex-Envelope Based Automated Quantitative Approach to Multi-Voxel 1H-MRS Applied to Brain Tumor Analysis.

2D 1H sLASER Long‐TE and 3D 31P Chemical Shift Imaging at 3 T for Monitoring Fasting‐Induced Changes in Brain Tumor Tissue

Magnetic resonance spectroscopic imaging in gliomas: clinical diagnosis and radiotherapy planning

Relation between MRS and Glioma Metabolism Boundary

Glial Tumors: Quantification and Segmentation from MRI and MRS

Relationship between multi-pool model-based chemical exchange saturation transfer imaging, intravoxel incoherent motion MRI, and 11C-methionine uptake on PET/CT in patients with gliomas

Utility of 3T single-voxel proton MR spectroscopy for differentiating intracranial meningiomas from intracranial enhanced mass lesions

Improved Detection of Target Metabolites in Brain Tumors with Intermediate TE, High SNR, and High Bandwidth Spin-Echo Sequence at 5T

Measurement of glycine in the human brain in vivo by 1H-MRS at 3 T: application in brain tumors

Early Metabolic Changes in 1H-MRSI Predictive for Survival in Patients With Newly Diagnosed High-grade Glioma

Tmet-23. Mass Spectrometry-Based Metabolic Profiling And Imaging Of Astrocyte And Glioblastoma Invasive Margin Cells

Imaging of increased peritumoral glutamate and glutamine in gliomas using 7T MRSI

Nimg-56. Magnetic Resonance Spectroscopy In The Post-Treatment Metabolic Characterization Of Brain Tumors Of Glial Origin Of Central Nervous System

Metabolic profiles of human brain parenchyma and glioma for rapid tissue diagnosis by targeted desorption electrospray ionization mass spectrometry

Analysis of normal metabolite concentration by proton MR spectroscopy using different repetition times